The interleukin-17F and IL-17A contribute mainly to the pathobiology of plaque psoriasis and the simultaneous blockade of both cytokines may lead to more complete suppression of inflammation and superior clinical outcomes than blocking IL-17A alone [4]. Here, IL17A is linked to psoriasis vulgaris.